<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04649203</url>
  </required_header>
  <id_info>
    <org_study_id>CTF-III-DM-2019</org_study_id>
    <nct_id>NCT04649203</nct_id>
  </id_info>
  <brief_title>Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy</brief_title>
  <acronym>CYLINDER</acronym>
  <official_title>Multicenter, Double-blind, Placebo-controlled Randomized Clinical Trial of Efficacy and Safety of the Drug Cytoflavin®, Administered Intravenously Followed by Oral Intake, in Patients With Diabetic Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>POLYSAN Scientific &amp; Technological Pharmaceutical Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>POLYSAN Scientific &amp; Technological Pharmaceutical Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of the most common complications of diabetes mellitus is diabetic polyneuropathy, which&#xD;
      leads to disability and reduces quality of life. The toxic effects of high glucose&#xD;
      concentrations contribute to the formation of ketoaldehyde free radicals, which, at an&#xD;
      increased rate of their formation, leads to the development of oxidative stress in the&#xD;
      nervous tissue. The planned study of the use of Cytoflavin® in diabetic polyneuropathy is&#xD;
      substantiated by its antioxidant effect, which, by analogy with alpha-lipoic acid&#xD;
      preparations, suggests its efficacy in the combined treatment of such patients. This clinical&#xD;
      study is being conducted to assess the efficacy and safety of Cytoflavin® versus Placebo in&#xD;
      diabetic polyneuropathy patients with type 2 diabetes. Study patients will receive study&#xD;
      medication, 10 IV infusions followed by 75 days of oral intake. Clinical efficacy will be&#xD;
      assessed by alleviation of symptoms (burning, numbness, pain and pricking), using the total&#xD;
      symptoms score(TSS), after the completion of the treatment course.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Actual">June 6, 2021</completion_date>
  <primary_completion_date type="Actual">March 29, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TSS (Total Symptom Score)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in total TSS score at Week 12 from baseline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Diabetic Neuropathies</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml/min, for 10 days + Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), 2 tablets 2 times a day, for 75 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml / min, for 10 days + Placebo, 2 tablets 2 times a day, for 75 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)</intervention_name>
    <description>The study drug will be administered in two phases: intravenous infusion of study drug for 10 days followed by oral administration of study drug for 75 days. Thus, the total duration of the study therapy is 12 weeks.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo comparator will be administered in two phases: intravenous infusion of placebo solution for 10 days followed by oral administration of placebo pills for 75 days. Thus, the total duration of the study therapy is 12 weeks.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form;&#xD;
&#xD;
          -  Men and women aged 45 to 74 (inclusive);&#xD;
&#xD;
          -  Confirmed diagnosis of type 2 diabetes lasting for 1 year or more;&#xD;
&#xD;
          -  Permanent scheme of therapy (without changing doses and drugs) by oral hypoglycemic&#xD;
             drugs and / or insulin, long-term or ultra-long (adjustment of insulin dose is&#xD;
             possible within 10% from baseline dose) and / or agonists of glucagon-like peptide-1&#xD;
             receptors (GLP-1) for at least 12 weeks before screening;&#xD;
&#xD;
          -  HbA1c from 7.0 and not higher than 10.0%;&#xD;
&#xD;
          -  BMI 22-40 kg / m2;&#xD;
&#xD;
          -  Symptomatic distal sensorimotor diabetic polyneuropathy;&#xD;
&#xD;
          -  Baseline TSS (Total Syptom Score) ˃5 points;&#xD;
&#xD;
          -  Score ≥2 by at least one of the TSS symptoms;&#xD;
&#xD;
          -  The severity of pain by the corresponding TSS subscale ≤ 2;&#xD;
&#xD;
          -  NISLL (Neuropathy Impairment Score Low Limbs) ≥ 2 points;&#xD;
&#xD;
          -  Patient consent to use adequate contraceptive methods for the entire study;&#xD;
&#xD;
          -  Consent to maintain a stable diet, exercise, therapy and diabetes control throughout&#xD;
             the study;&#xD;
&#xD;
          -  Ability to comply with all protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women, or women planning a pregnancy during a clinical trial;&#xD;
&#xD;
          -  Type 1 diabetes and other specific types of diabetes;&#xD;
&#xD;
          -  Acute metabolic complications of diabetes such as ketoacidosis or hyperosmolar state&#xD;
             within 6 months prior to screening;&#xD;
&#xD;
          -  Therapy with short and ultra-short insulin within 3 months before screening;&#xD;
&#xD;
          -  Fasting plasma glucose at screening&gt; 15 mmol / l;&#xD;
&#xD;
          -  The presence of severe complications of diabetes;&#xD;
&#xD;
          -  Epilepsy, epileptiform seizures, head trauma with loss of consciousness, tumor,&#xD;
             inflammatory and demyelinating diseases of the central nervous system;&#xD;
&#xD;
          -  Diseases requiring prior or current treatment by systemic corticosteroid drugs,&#xD;
             cytostatics or penicillamine;malignant neoplasms within the last 5 years (excluding&#xD;
             basal cell carcinoma);&#xD;
&#xD;
          -  Cardiovascular diseases in the stage of decompensation at present or within 3 months&#xD;
             before screening;&#xD;
&#xD;
          -  Uncontrolled arterial hypertension with systolic arterial pressure&gt; 180 mm Hg and&#xD;
             diastolic blood pressure&gt; 110 mm Hg at screening;&#xD;
&#xD;
          -  Nephrotic syndrome, severe chronic renal failure or significant kidney disease with a&#xD;
             level of glomerular filtration rate (GFR) &lt;30 ml / min;&#xD;
&#xD;
          -  Active viral (hepatitis B and C) or cirrhotic liver disease; increased aspartate&#xD;
             aminotransferase (AST) or serum alanine aminotransferase (ALT) 3 times from upper&#xD;
             normal limit; increased total bilirubin 2 times from upper normal limit;&#xD;
&#xD;
          -  HIV; a severe infectious disease within 30 days before screening;&#xD;
&#xD;
          -  Anemia (hemoglobin ≤ 105 g / l in women or ≤ 115 g / l in men); acute blood loss or&#xD;
             donation of at least one unit of blood (500 ml) or blood transfusion within the&#xD;
             previous 12 weeks;&#xD;
&#xD;
          -  Drug or alcohol abuse;&#xD;
&#xD;
          -  Intake of Cytoflavin® for 3 months before screening;&#xD;
&#xD;
          -  Known allergies, hypersensitivity or contraindications to the drug Cytoflavin® or its&#xD;
             components;&#xD;
&#xD;
          -  Intake of alpha-lipoic acid, thiamine derivatives, pyridoxine, cyanocobalamin&#xD;
             (excluding multivitamins), antidepressants and derivatives of gabapentin within 3&#xD;
             months before screening;&#xD;
&#xD;
          -  Use of other investigational drugs within 3 months prior to screening;&#xD;
&#xD;
          -  Inability to read or write; unwillingness to understand and follow protocol&#xD;
             procedures; non-compliance with the protocol requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City Clinical Hospital n.a. V.P.Demikhov</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital n.a.M.E.Zhadkevitch</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #13 Avtozavodsky district</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center for Eco-safety, Ltd.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Astarta&quot; Ltd.</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City General Hospital №2</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Outpatient Clinic #51</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I. P. Pavlov 1st St. Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North-West State Medical University named after I.I. Mechnikov</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Consultative and diagnostic center with a polyclinic&quot; of the Administrative Department of the President of the Russian Federation</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almazov National Medical Research Centre</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Outpatient Clinic #117</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDICA Ltd.</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Diabetes&quot; medical center</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University n.a. V.I.Razumovsky</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ YAO &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Peripheral Nervous System Diseases</keyword>
  <keyword>Antioxidants</keyword>
  <keyword>Succinic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

